Caliway Biopharmaceuticals (6919) Q2 2025 earnings summary

Executive summary

• Focused on new drug development for aesthetic medicine and chronic inflammation, with shares listed on TWSE since October 2024.

• Consolidated financials reviewed by KPMG, with a qualified conclusion due to unreviewed non-significant subsidiaries.

• Board authorized the financial statements on August 8, 2025.

Financial highlights

• Operating revenue for H1 2025 was NT$12,212K, up slightly from NT$11,814K year-over-year.

• Net loss for H1 2025 was NT$424,378K, compared to NT$395,122K in H1 2024.

• Basic loss per share for H1 2025 was NT$0.28, unchanged from H1 2024.

• Cash and cash equivalents increased to NT$7,573,475K as of June 30, 2025, from NT$2,650,378K a year earlier.

• Significant foreign exchange losses of NT$127,098K in H1 2025, compared to a gain of NT$19,008K in H1 2024.

Outlook and guidance

• Adoption of new IFRS standards is not expected to have a significant impact.

• The company continues to evaluate the impact of IFRS 18, effective January 2027.